Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint Phase 2 in Knee OA
NCT03122860Phase 2Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lorecivivint in osteoarthritis (OA) (6 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Weekly Average of Daily Pain Numeric Rating Scale at 24 weeks, WOMAC Pain Subscore at 24 weeks and 2 more. Started Apr 2017; status: completed.
02
Drugs
lorecivivint
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03122860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122860.